Skip to main content
Fig. 5 | Genome Medicine

Fig. 5

From: Germline HLA-B evolutionary divergence influences the efficacy of immune checkpoint blockade therapy in gastrointestinal cancer

Fig. 5

Correlation of HLA-B HED with genomic determinants and mutational patterns in patients with HLA-B heterozygosity. a, b Correlation of HLA-B HED with the CNA burden, TMB and neoantigen burden in the MSI-H (a) or MSS (b) subpopulations (two-sided Spearman’s correlation) in patients with HLA-B heterozygosity (n = 71). c Mutation frequency of driver genes between the high- and low-HLA-B HED subgroups in patients with HLA-B heterozygosity (n = 71) were compared using mafCompare function of the maftools R package. d Oncoplot of the potentially differentially mutated driver genes. e Association of HLA-B HED with TP53 mutations. f Kaplan-Meier survival analysis of OS and PFS between patients with or without TP53 mutations in patients with HLA-B heterozygosity (PFS information was not available for one patient). HLA-B HED high was designated as HLA-B HED > 8.61

Back to article page